Dostarlimab
- Generic Name
- Dostarlimab
- Brand Names
- Jemperli
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2022215-59-2
- Unique Ingredient Identifier
- P0GVQ9A4S5
- Background
Dostarlimab is an IgG humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically att...
- Indication
Dostarlimab-gxly is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed despite ongoing or prior treatment with a platinum-containing chemotherapy regimen.
...
- Associated Conditions
- Advanced Microsatellite Instability High Endometrial Carcinoma, Advanced Mismatch Repair-deficient (dMMR) Endometrial Cancer, Advanced Mismatch repair deficient (dMMR) solid tumors, Recurrent Microsatellite Instability (MSI)-High Endometrial Cancer, Recurrent Mismatch Repair-deficient (dMMR) Endometrial Cancer, Recurrent Mismatch repair deficient (dMMR) solid tumors
- Associated Therapies
- -
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT04544995
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 244
- Registration Number
- NCT04446351
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Niraparib + Dostarlimab + RT in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT04409002
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Trisha Wise-Draper
- Target Recruit Count
- 23
- Registration Number
- NCT04313504
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 464
- Registration Number
- NCT04126200
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 66
- Registration Number
- NCT04068753
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 785
- Registration Number
- NCT03981796
- Locations
- 🇬🇧
GSK Investigational Site, Truro, United Kingdom
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03955471
- Locations
- 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT03843359
- Locations
- 🇪🇸
GSK Investigational Site, Madrid, Spain
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT03739710
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.